1120 related articles for article (PubMed ID: 28004055)
1. Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease.
Kaur H; Corscadden K; Ware J; Othman M
Thromb Haemost; 2017 Feb; 117(3):543-555. PubMed ID: 28004055
[TBL] [Abstract][Full Text] [Related]
2. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation.
Guerrero JA; Kyei M; Russell S; Liu J; Gartner TK; Storrie B; Ware J
Blood; 2009 Dec; 114(27):5541-6. PubMed ID: 19808696
[TBL] [Abstract][Full Text] [Related]
3. In vivo relevance for platelet glycoprotein Ibalpha residue Tyr276 in thrombus formation.
Guerrero JA; Shafirstein G; Russell S; Varughese KI; Kanaji T; Liu J; Gartner TK; Bäumler W; Jarvis GE; Ware J
J Thromb Haemost; 2008 Apr; 6(4):684-91. PubMed ID: 18339097
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo.
Bergmeier W; Piffath CL; Cheng G; Dole VS; Zhang Y; von Andrian UH; Wagner DD
Circ Res; 2004 Oct; 95(7):677-83. PubMed ID: 15345652
[TBL] [Abstract][Full Text] [Related]
5. Targeting platelet GPIbβ reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis.
Maurer E; Tang C; Schaff M; Bourdon C; Receveur N; Ravanat C; Eckly A; Hechler B; Gachet C; Lanza F; Mangin PH
Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1221-9. PubMed ID: 23559635
[TBL] [Abstract][Full Text] [Related]
6. Dual roles of fucoidan-GPIbα interaction in thrombosis and hemostasis: implications for drug development targeting GPIbα.
Shen C; Mackeigan DT; Shoara AA; Xu R; Bhoria P; Karakas D; Ma W; Cerenzia E; Chen Z; Hoard B; Lin L; Lei X; Zhu G; Chen P; Johnson PE; Ni H
J Thromb Haemost; 2023 May; 21(5):1274-1288. PubMed ID: 36732162
[TBL] [Abstract][Full Text] [Related]
7. Humanized GPIbα-von Willebrand factor interaction in the mouse.
Kanaji S; Orje JN; Kanaji T; Kamikubo Y; Morodomi Y; Chen Y; Zarpellon A; Eberhardt J; Forli S; Fahs SA; Sood R; Haberichter SL; Montgomery RR; Ruggeri ZM
Blood Adv; 2018 Oct; 2(19):2522-2532. PubMed ID: 30287479
[TBL] [Abstract][Full Text] [Related]
8. Function of von Willebrand factor in haemostasis and thrombosis.
Reininger AJ
Haemophilia; 2008 Nov; 14 Suppl 5():11-26. PubMed ID: 18786007
[TBL] [Abstract][Full Text] [Related]
9. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val.
Doggett TA; Girdhar G; Lawshe A; Miller JL; Laurenzi IJ; Diamond SL; Diacovo TG
Blood; 2003 Jul; 102(1):152-60. PubMed ID: 12637314
[TBL] [Abstract][Full Text] [Related]
11. P-selectin can promote thrombus propagation independently of both von Willebrand factor and thrombospondin-1 in mice.
Prakash P; Nayak MK; Chauhan AK
J Thromb Haemost; 2017 Feb; 15(2):388-394. PubMed ID: 27943541
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of GPIbalpha-vWF-A1 tether bond under flow: effect of GPIbalpha mutations on the association and dissociation rates.
Kumar RA; Dong JF; Thaggard JA; Cruz MA; López JA; McIntire LV
Biophys J; 2003 Dec; 85(6):4099-109. PubMed ID: 14645097
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease.
Matsubara Y; Murata M; Sugita K; Ikeda Y
J Thromb Haemost; 2003 Oct; 1(10):2198-205. PubMed ID: 14521605
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
Miller JL; Kupinski JM; Castella A; Ruggeri ZM
J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
16. Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect.
Othman M; Kaur H; Emsley J
Semin Thromb Hemost; 2013 Sep; 39(6):663-73. PubMed ID: 23934752
[TBL] [Abstract][Full Text] [Related]
17. Platelet-type von Willebrand disease: Local disorder of the platelet GPIbα β-switch drives high-affinity binding to von Willebrand factor.
Tischer A; Machha VR; Moon-Tasson L; Auton M
J Thromb Haemost; 2019 Dec; 17(12):2022-2034. PubMed ID: 31448872
[TBL] [Abstract][Full Text] [Related]
18. Refrigeration-Induced Binding of von Willebrand Factor Facilitates Fast Clearance of Refrigerated Platelets.
Chen W; Druzak SA; Wang Y; Josephson CD; Hoffmeister KM; Ware J; Li R
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2271-2279. PubMed ID: 29097365
[TBL] [Abstract][Full Text] [Related]
19. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.
Bergmeier W; Piffath CL; Goerge T; Cifuni SM; Ruggeri ZM; Ware J; Wagner DD
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16900-5. PubMed ID: 17075060
[TBL] [Abstract][Full Text] [Related]
20. Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway.
Bury L; Falcinelli E; Mezzasoma AM; Guglielmini G; Momi S; Gresele P
Haematologica; 2022 Jul; 107(7):1643-1654. PubMed ID: 34407603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
